| Project/Area Number |
61570849
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
KANAI Atushi Juntendo University, School of Medicine, Department of Ophthalmology, 医学部, 助教授 (00053059)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKANO Toshiyuki Juntendo University, School of Medicine, Department of Ophtalmology, 医学部, 助手 (30163231)
KOBAYASHI Chihiro Juntendo University, School of Medicine, Department of Ophthalmology, 医学部, 助手 (20162000)
MURAKAMI Akira Juntendo University, School of Meicine, Department of Ophthalmology., 医学部, 助手 (90157743)
MINAMI Shuichiro Juntendo University,School of Medicine, Department of Opthalmology, 医学部, 助手 (10166085)
|
|---|
| Project Period (FY) |
1986 – 1987
|
| Project Status |
Completed (Fiscal Year 1987)
|
| Budget Amount *help |
¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 1987: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1986: ¥1,000,000 (Direct Cost: ¥1,000,000)
|
|---|
| Keywords | Immunosuppressive agents / Eye drops / Sunconjunctival injection / Rabbit / Corneal trnasplantation / Mizoribine / FK-506 / 家兎 / 家兎角膜移植 / 免疫抑制剤の点眼 / 免疫反応 |
|---|
| Research Abstract |
Corneal graft rejection is one of the leading causes of failure in corneal graft surgery. The mainatray of the treatment of corneal graft rejection is the corticosteroid. However, steroid is not without side effects. The first study was to test the efficacy of systemically and topically administered Mizoribine in preventing corneal allograft rejection in rabbits. They were divided into 6 groups. Group 1:subcutaneous injection of Mizoribine(10 mb/kg/day), Group 2: topical Mizoribine 10% 5 times daily, Group 3:5%, Group 5:1%, and Group6: control. The survival times of grafts in Group 1,2,3,and 4 were longer than that of Group 6. Based on the results of animal experiments, Mizoribine was clinically test on 87 patients after thier corneal transplantation. 100 mg per day of Mizoribine was given orally. 14 out of 60 eyes(23.3%) had graft rejection. 58 out of 126 eyes(46.0%) in control had graft rejection. 4 out of 27 eyes(14.8%) which were given 10% Mizoribine eye drops had graft rejction. 45 out of 108 eyes(41.7%) in control eyes had graft rejection. The difference of both groups were statistically significant at 1% level. The second study was to test the effecacy of subconjunctival administered FK-506 in preventing corneal allograft rejection in rabbits. Group 1 : subconjunctival injection of FK-506 0.1mg/kg twice a week. Group 2: sunconjunctival injection of placebo twice a week. The survival times of graftrs in Group 1 during 100 days were longer than that of Group 2. There was no toxicity that could be attributed to topically administered FK-506.
|
